Abstract:Survival rates for pediatric cancer have steadily improved over time but it remains a significant cause of morbidity and mortality among children. Infections are a major complication of cancer and its treatment. Community acquired respiratory viral infections (CRV) in these patients increase morbidity, mortality and can lead to delay in chemotherapy. These are the result of infections with a heterogeneous group of viruses including RNA viruses, such as respiratory syncytial virus (RSV), influenza virus (IV), parainfluenza virus (PIV), metapneumovirus (HMPV), rhinovirus (RhV), and coronavirus (CoV). These infections maintain a similar seasonal pattern to those of immunocompetent patients. Clinical manifestations vary significantly depending on the type of virus and the type and degree of immunosuppression, ranging from asymptomatic or mild disease to rapidly progressive fatal pneumonia Infections in this population are characterized by a high rate of progression from upper to lower respiratory tract infection and prolonged viral shedding. Use of corticosteroids and immunosuppressive therapy are risk factors for severe disease. The clinical course is often difficult to predict, and clinical signs are unreliable. Accurate prognostic viral and immune markers, which have become part of the standard of care for systemic viral infections, are currently lacking; and management of CRV infections remains controversial. Defining effective prophylactic and therapeutic strategies is challenging, especially considering, the spectrum of immunocompromised patients, the variety of respiratory viruses, and the presence of other opportunistic infections and medical problems. Prevention remains one of the most important strategies against these viruses. Early diagnosis, supportive care and antivirals at an early stage, when available and indicated, have proven beneficial. However, with the exception of neuraminidase inhibitors for influenza infection, there are no accepted treatments. In high-risk patients, pre-emptive treatment with antivirals for upper respiratory tract infection (URTI) to decrease progression to LRTI is a common strategy. In the future, viral load and immune markers may prove beneficial in predicting severe disease, supporting decision making and monitor treatment in this population.

Infection prophylaxis and management of viral infection

Community-Acquired Respiratory Viruses Post–Lung Transplant

SARS-CoV-2 Infection in Transplant-Related Biology: Where Do We Stand?

Viral respiratory tract infections in transplant patients: epidemiology, recognition and management

Opportunistic Infections Post-Lung Transplantation: Viral, Fungal, and Mycobacterial

The changing landscape of infections in the lung transplant recipient

Clinical Impact of Community-Acquired Respiratory Viruses in Patients With Solid Organ Transplants

Innate and adaptive effector immune drivers of cytomegalovirus disease in lung transplantation: a double-edged sword

RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

Impact of Respiratory Viral Infections in Transplant Recipients

Cytomegalovirus Infection Is Associated with Development of Chronic Lung Allograft Dysfunction

Post-transplant Viral Respiratory Infections in the Older Patient: Epidemiology, Diagnosis, and Management

What's New: Updates on Cytomegalovirus in Solid Organ Transplantation

Immunopathology of lung transplantation: from infection to rejection and vice versa

Cytomegalovirus infection in liver transplant recipients: updates on clinical management

Respiratory Viral Infections in Patients With Cancer or Undergoing Hematopoietic Cell Transplant

Antiviral Stewardship in Transplantation

Are any specific respiratory viruses more severe than others in recipients of allogeneic stem cell transplantation? A focus on lower respiratory tract disease

Human herpesvirus-6, HHV-8 and parvovirus B19 after allogeneic hematopoietic cell transplant: the lesser-known viral complications

Recent advances in understanding and managing infectious diseases in solid organ transplant recipients

Approach to hematopoietic cell transplant candidates with respiratory viral detection